Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic non-A non-B hepatitis treated with interferon].

K Bjøro1, E Schrumpf, K Elgjo

  • 1Medisinsk avdeling A, Rikshospitalet, Oslo.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|April 30, 1990
PubMed
Summary

Recombinant interferon alpha 2-B offers a promising treatment for non-A non-B hepatitis. This therapy normalized liver function and structure in a patient, warranting further investigation for broader application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid antigens in bile from patients with chronic liver diseases activate natural killer T cells.

Clinical and experimental immunology·2020
Same author

Natural killer T cells mediate inflammation in the bile ducts.

Mucosal immunology·2018
Same author

Secondary Osteoporosis in Liver Transplant Recipients: a Longitudinal Study in Patients With and Without Cholestatic Liver Disease.

Scandinavian journal of gastroenterology·2017
Same author

Difference in the distribution of low-molecular-weight peptides and amino-acids in normal and malignant-cells and tissues.

Oncology reports·2011
Same author

Validation of a cholangiographic prognostic model in primary sclerosing cholangitis.

Endoscopy·2010
Same author

Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis.

Genes and immunity·2007

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Non-A non-B hepatitis presents significant diagnostic and therapeutic challenges.
  • Emerging research suggests interferon as a potential therapeutic agent for this condition.

Observation:

  • A patient diagnosed with non-A non-B hepatitis was treated with recombinant interferon alpha 2-B.
  • Treatment duration was nine months.

Findings:

  • The patient exhibited normalization of both biochemical and morphological liver parameters following treatment.
  • This indicates a positive therapeutic response to recombinant interferon alpha 2-B.

Implications:

  • Recombinant interferon alpha 2-B demonstrates potential efficacy in treating non-A non-B hepatitis.

Related Experiment Videos

  • Further research is necessary to determine optimal dosages and confirm efficacy in larger patient cohorts.